The first patient has been treated using NorthStar Medical Radioisotopes' electron accelerator-generated copper-67 (Cu-67) radioisotope in Clarity Pharmaceutical's U.S.-based SARTATE peptide receptor radionuclide therapy trial.
The phase I/IIa trial is investigating the use of copper-64 (Cu-64) and copper-67 (Cu-67) for treatment of neuroblastoma and neuroendocrine tumors.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
